StockInvestor editor Matt Coffina breaks down how cash flow analyses, uncertainty ratings, and economic moats play key roles in our equity valuation methodology.
Morningstar investment experts Russ Kinnel, Matt Coffina, Josh Peters, and Sam Lee answer viewer questions about the current market and the best opportunities in stocks, funds, and ETFs today.
UnitedHealth stock has advanced as investors saw reform would not be as negative as anticipated, and there is still upside from here.
Regardless of when and how the justices rule on the Affordable Care Act as well as the best- and worst-case scenarios, company valuations should see little change, says Morningstar's Matt Coffina.
Shareholders would be well-served by the pharmacy benefit managers' merger, but regulators are unlikely to sign off on it, says Morningstar's Matt Coffina.
Read one professor's take, and join the discussion!
Although a new public health-care plan could drastically cut MCOs' fair values, that legislation is likely not passable.
Some great funds see attractive opportunities in the health-care sector.
Fancy names can't make up for bad businesses.
The Fed steps into the storm; stagflation worries persist.